Colorcon launches Opadry Enteric for use with hydro-alcoholic media
A fully formulated one-step system providing simple preparation and ease-of-use for film coating.
Colorcon has announced another innovative addition to their portfolio of delayed-release coatings for pharmaceutical applications. This latest development incorporates hydroxypropyl methylcellulose phthalate (hypromellose phthalate or HPMC-P) as the functional polymer in an advanced one-step film coating system offering enteric performance for hydro-alcoholic applications.
Opadry Enteric is a fully formulated one-step system providing simple preparation and ease-of-use for film coating; resulting in reduced inventory and QC testing compared to multi-component coating systems. This new system provides a further option to the company's existing Opadry delayed-release product line based on acrylic and PVAP polymers.
Dr Daniel To, Product Development Manager, explains: “As a fully formulated system Opadry Enteric, based on HPMC-P, brings not only convenience but also reduces potential errors of raw material handling and application during manufacturing. Our application data, generated during the product’s development, clearly demonstrates consistent and stable enteric performance for a number of APIs.”
Greater efficiency for solvent coating
Kelly Boyer, General Manager, Film Coatings at Colorcon notes: “Opadry Enteric is formulated for use with hydro-alcoholic media and can be color matched to meet the marketing and brand needs of pharmaceutical products. As a one-step hydro-alcoholic coating, preparation time is significantly reduced and, by using Colorcon’s expertise in color matching, batch-to-batch variability is eliminated.”
This new fully formulated delayed release coating, providing enteric protection represents Colorcon’s continued innovation and leadership in developing formulated film coating systems that bring enhanced functionality along with improved convenience for pharmaceutical formulators.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.